

Global Live Attenuated Influenza Vaccine (LAIV) Market Research Report 2024, Forecast to 2032

<https://marketpublishers.com/r/GFCD080E407CEN.html>

Date: October 2024

Pages: 139

Price: US\$ 3,200.00 (Single User License)

ID: GFCD080E407CEN

Abstracts

Report Overview

A Live Attenuated Influenza Vaccine (LAIV), also known as the 'nasal spray' or 'intranasal' flu vaccine, is a type of influenza vaccine that is designed to provide immunity against the influenza virus. Unlike traditional injectable influenza vaccines, which contain inactivated (killed) virus particles, LAIV contains a weakened, live influenza virus. This live virus is attenuated, meaning it has been modified to reduce its virulence (ability to cause disease) while still retaining the capacity to stimulate an immune response.

The global Live Attenuated Influenza Vaccine (LAIV) market size was estimated at USD 7740.50 million in 2023 and is projected to reach USD 13414.31 million by 2032, exhibiting a CAGR of 6.30% during the forecast period.

North America Live Attenuated Influenza Vaccine (LAIV) market size was estimated at USD 2240.67 million in 2023, at a CAGR of 5.40% during the forecast period of 2024 through 2032.

This report provides a deep insight into the global Live Attenuated Influenza Vaccine (LAIV) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore,

it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Live Attenuated Influenza Vaccine (LAIV) Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Live Attenuated Influenza Vaccine (LAIV) market in any manner.

Global Live Attenuated Influenza Vaccine (LAIV) Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Sanofi Pasteur

AstraZeneca

CSL

Abbott

GlaxoSmithKline

Serum Institute

Fluenz Tetra

Cytiva

BioDiem

FluMist

GSK

ChangChun High & New Technology

BCHT Biotechnology

Market Segmentation (by Type)

Trivalent Flu Vaccine

Quadrivalent Flu Vaccine

Market Segmentation (by Application)

Hospital

Clinic

Public Health Agency

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Live Attenuated Influenza Vaccine (LAIV) Market

Overview of the regional outlook of the Live Attenuated Influenza Vaccine (LAIV) Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Live Attenuated Influenza Vaccine (LAIV) Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region from the consumer side and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Live Attenuated Influenza Vaccine (LAIV), their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development

potential of each region during the forecast period.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment during the forecast period.

Chapter 13 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Live Attenuated Influenza Vaccine (LAIV)

1.2 Key Market Segments

1.2.1 Live Attenuated Influenza Vaccine (LAIV) Segment by Type

1.2.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET OVERVIEW

2.1 Global Market Overview

2.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Estimates and Forecasts (2019-2032)

2.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Estimates and Forecasts (2019-2032)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET COMPETITIVE LANDSCAPE

3.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Manufacturers (2019-2024)

3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Manufacturers (2019-2024)

3.3 Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4 Global Live Attenuated Influenza Vaccine (LAIV) Average Price by Manufacturers (2019-2024)

3.5 Manufacturers Live Attenuated Influenza Vaccine (LAIV) Sales Sites, Area Served, Product Type

3.6 Live Attenuated Influenza Vaccine (LAIV) Market Competitive Situation and Trends

- 3.6.1 Live Attenuated Influenza Vaccine (LAIV) Market Concentration Rate
- 3.6.2 Global 5 and 10 Largest Live Attenuated Influenza Vaccine (LAIV) Players Market Share by Revenue
- 3.6.3 Mergers & Acquisitions, Expansion

4 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) INDUSTRY CHAIN ANALYSIS

- 4.1 Live Attenuated Influenza Vaccine (LAIV) Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Market Restraints
- 5.5 Industry News
 - 5.5.1 New Product Developments
 - 5.5.2 Mergers & Acquisitions
 - 5.5.3 Expansions
 - 5.5.4 Collaboration/Supply Contracts
- 5.6 Industry Policies

6 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2019-2024)
- 6.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Market Share by Type (2019-2024)
- 6.4 Global Live Attenuated Influenza Vaccine (LAIV) Price by Type (2019-2024)

7 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Sales by Application (2019-2024)
- 7.3 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Application (2019-2024)
- 7.4 Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2019-2024)

8 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET CONSUMPTION BY REGION

- 8.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
 - 8.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region
 - 8.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region
- 8.2 North America
 - 8.2.1 North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
 - 8.2.2 U.S.
 - 8.2.3 Canada
 - 8.2.4 Mexico
- 8.3 Europe
 - 8.3.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country
 - 8.3.2 Germany
 - 8.3.3 France
 - 8.3.4 U.K.
 - 8.3.5 Italy
 - 8.3.6 Russia
- 8.4 Asia Pacific
 - 8.4.1 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region
 - 8.4.2 China
 - 8.4.3 Japan
 - 8.4.4 South Korea
 - 8.4.5 India
 - 8.4.6 Southeast Asia
- 8.5 South America
 - 8.5.1 South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country
 - 8.5.2 Brazil
 - 8.5.3 Argentina
 - 8.5.4 Columbia
- 8.6 Middle East and Africa

8.6.1 Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET PRODUCTION BY REGION

9.1 Global Production of Live Attenuated Influenza Vaccine (LAIV) by Region (2019-2024)

9.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Region (2019-2024)

9.3 Global Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)

9.4 North America Live Attenuated Influenza Vaccine (LAIV) Production

9.4.1 North America Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)

9.4.2 North America Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)

9.5 Europe Live Attenuated Influenza Vaccine (LAIV) Production

9.5.1 Europe Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)

9.5.2 Europe Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)

9.6 Japan Live Attenuated Influenza Vaccine (LAIV) Production (2019-2024)

9.6.1 Japan Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)

9.6.2 Japan Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)

9.7 China Live Attenuated Influenza Vaccine (LAIV) Production (2019-2024)

9.7.1 China Live Attenuated Influenza Vaccine (LAIV) Production Growth Rate (2019-2024)

9.7.2 China Live Attenuated Influenza Vaccine (LAIV) Production, Revenue, Price and Gross Margin (2019-2024)

10 KEY COMPANIES PROFILE

10.1 Sanofi Pasteur

10.1.1 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Basic Information

10.1.2 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview

10.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Market

Performance

10.1.4 Sanofi Pasteur Business Overview

10.1.5 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis

10.1.6 Sanofi Pasteur Recent Developments

10.2 AstraZeneca

10.2.1 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Basic Information

10.2.2 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview

10.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Market

Performance

10.2.4 AstraZeneca Business Overview

10.2.5 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis

10.2.6 AstraZeneca Recent Developments

10.3 CSL

10.3.1 CSL Live Attenuated Influenza Vaccine (LAIV) Basic Information

10.3.2 CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview

10.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Product Market Performance

10.3.4 CSL Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis

10.3.5 CSL Business Overview

10.3.6 CSL Recent Developments

10.4 Abbott

10.4.1 Abbott Live Attenuated Influenza Vaccine (LAIV) Basic Information

10.4.2 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview

10.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Market Performance

10.4.4 Abbott Business Overview

10.4.5 Abbott Recent Developments

10.5 GlaxoSmithKline

10.5.1 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Basic Information

10.5.2 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview

10.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Market

Performance

10.5.4 GlaxoSmithKline Business Overview

10.5.5 GlaxoSmithKline Recent Developments

10.6 Serum Institute

10.6.1 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Basic Information

- 10.6.2 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview
- 10.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
- 10.6.4 Serum Institute Business Overview
- 10.6.5 Serum Institute Recent Developments
- 10.7 Fluenz Tetra
 - 10.7.1 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Basic Information
 - 10.7.2 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.7.4 Fluenz Tetra Business Overview
 - 10.7.5 Fluenz Tetra Recent Developments
- 10.8 Cytiva
 - 10.8.1 Cytiva Live Attenuated Influenza Vaccine (LAIV) Basic Information
 - 10.8.2 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.8.4 Cytiva Business Overview
 - 10.8.5 Cytiva Recent Developments
- 10.9 BioDiem
 - 10.9.1 BioDiem Live Attenuated Influenza Vaccine (LAIV) Basic Information
 - 10.9.2 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.9.4 BioDiem Business Overview
 - 10.9.5 BioDiem Recent Developments
- 10.10 FluMist
 - 10.10.1 FluMist Live Attenuated Influenza Vaccine (LAIV) Basic Information
 - 10.10.2 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.10.4 FluMist Business Overview
 - 10.10.5 FluMist Recent Developments
- 10.11 GSK
 - 10.11.1 GSK Live Attenuated Influenza Vaccine (LAIV) Basic Information
 - 10.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview
 - 10.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Product Market Performance
 - 10.11.4 GSK Business Overview
 - 10.11.5 GSK Recent Developments
- 10.12 ChangChun High and New Technology
 - 10.12.1 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Basic Information

10.12.2 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview

10.12.3 ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance

10.12.4 ChangChun High and New Technology Business Overview

10.12.5 ChangChun High and New Technology Recent Developments

10.13 BCHT Biotechnology

10.13.1 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Basic Information

10.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview

10.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Market Performance

10.13.4 BCHT Biotechnology Business Overview

10.13.5 BCHT Biotechnology Recent Developments

11 LIVE ATTENUATED INFLUENZA VACCINE (LAIV) MARKET FORECAST BY REGION

11.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast

11.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Region

11.2.1 North America Market Size Forecast by Country

11.2.2 Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country

11.2.3 Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region

11.2.4 South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Consumption of Live Attenuated Influenza Vaccine (LAIV) by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2032)

12.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Type (2025-2032)

12.1.1 Global Forecasted Sales of Live Attenuated Influenza Vaccine (LAIV) by Type (2025-2032)

12.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Type (2025-2032)

12.1.3 Global Forecasted Price of Live Attenuated Influenza Vaccine (LAIV) by Type (2025-2032)

12.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Forecast by Application (2025-2032)

12.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by Application

12.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) Forecast by Application (2025-2032)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Live Attenuated Influenza Vaccine (LAIV) Market Size Comparison by Region (M USD)

Table 5. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Manufacturers (2019-2024)

Table 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Influenza Vaccine (LAIV) as of 2022)

Table 10. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/MT) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Live Attenuated Influenza Vaccine (LAIV) Sales Sites and Area Served

Table 12. Manufacturers Live Attenuated Influenza Vaccine (LAIV) Product Type

Table 13. Global Live Attenuated Influenza Vaccine (LAIV) Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Live Attenuated Influenza Vaccine (LAIV)

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Live Attenuated Influenza Vaccine (LAIV) Market Challenges

Table 22. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Type (K MT)

Table 23. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Type (M USD)

Table 24. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Type (2019-2024)

Table 25. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2019-2024)

Table 26. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) by Type (2019-2024)

Table 27. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Share by Type (2019-2024)

Table 28. Global Live Attenuated Influenza Vaccine (LAIV) Price (USD/MT) by Type (2019-2024)

Table 29. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) by Application

Table 30. Global Live Attenuated Influenza Vaccine (LAIV) Market Size by Application

Table 31. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2019-2024) & (K MT)

Table 32. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application (2019-2024)

Table 33. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Application (2019-2024) & (M USD)

Table 34. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2019-2024)

Table 35. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2019-2024)

Table 36. Global Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K MT)

Table 37. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2019-2024)

Table 38. North America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K MT)

Table 39. Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K MT)

Table 40. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K MT)

Table 41. South America Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2019-2024) & (K MT)

Table 42. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2019-2024) & (K MT)

Table 43. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT) by Region (2019-2024)

Table 44. Global Live Attenuated Influenza Vaccine (LAIV) Revenue (US\$ Million) by Region (2019-2024)

Table 45. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by

Region (2019-2024)

Table 46. Global Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 47. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 48. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 49. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 50. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 51. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Basic Information

Table 52. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 53. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 54. Sanofi Pasteur Business Overview

Table 55. Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis

Table 56. Sanofi Pasteur Recent Developments

Table 57. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Basic Information

Table 58. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 59. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 60. AstraZeneca Business Overview

Table 61. AstraZeneca Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis

Table 62. AstraZeneca Recent Developments

Table 63. CSL Live Attenuated Influenza Vaccine (LAIV) Basic Information

Table 64. CSL Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 65. CSL Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 66. CSL Live Attenuated Influenza Vaccine (LAIV) SWOT Analysis

Table 67. CSL Business Overview

Table 68. CSL Recent Developments

Table 69. Abbott Live Attenuated Influenza Vaccine (LAIV) Basic Information

Table 70. Abbott Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 71. Abbott Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 72. Abbott Business Overview

Table 73. Abbott Recent Developments

Table 74. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Basic Information

Table 75. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 76. GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 77. GlaxoSmithKline Business Overview
Table 78. GlaxoSmithKline Recent Developments
Table 79. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 80. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 81. Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 82. Serum Institute Business Overview
Table 83. Serum Institute Recent Developments
Table 84. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 85. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 86. Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 87. Fluenz Tetra Business Overview
Table 88. Fluenz Tetra Recent Developments
Table 89. Cytiva Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 90. Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 91. Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Cytiva Business Overview
Table 93. Cytiva Recent Developments
Table 94. BioDiem Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 95. BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 96. BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. BioDiem Business Overview
Table 98. BioDiem Recent Developments
Table 99. FluMist Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 100. FluMist Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 101. FluMist Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. FluMist Business Overview
Table 103. FluMist Recent Developments
Table 104. GSK Live Attenuated Influenza Vaccine (LAIV) Basic Information
Table 105. GSK Live Attenuated Influenza Vaccine (LAIV) Product Overview
Table 106. GSK Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 107. GSK Business Overview

Table 108. GSK Recent Developments

Table 109. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Basic Information

Table 110. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 111. ChangChun High and New Technology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 112. ChangChun High and New Technology Business Overview

Table 113. ChangChun High and New Technology Recent Developments

Table 114. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Basic Information

Table 115. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Overview

Table 116. BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2019-2024)

Table 117. BCHT Biotechnology Business Overview

Table 118. BCHT Biotechnology Recent Developments

Table 119. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2025-2032) & (K MT)

Table 120. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2025-2032) & (M USD)

Table 121. North America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2025-2032) & (K MT)

Table 122. North America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2025-2032) & (M USD)

Table 123. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2025-2032) & (K MT)

Table 124. Europe Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2025-2032) & (M USD)

Table 125. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Region (2025-2032) & (K MT)

Table 126. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region (2025-2032) & (M USD)

Table 127. South America Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Country (2025-2032) & (K MT)

Table 128. South America Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Country (2025-2032) & (M USD)

Table 129. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV)
Consumption Forecast by Country (2025-2032) & (Units)

Table 130. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Market
Size Forecast by Country (2025-2032) & (M USD)

Table 131. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Type
(2025-2032) & (K MT)

Table 132. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by
Type (2025-2032) & (M USD)

Table 133. Global Live Attenuated Influenza Vaccine (LAIV) Price Forecast by Type
(2025-2032) & (USD/MT)

Table 134. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) Forecast by
Application (2025-2032)

Table 135. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by
Application (2025-2032) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Live Attenuated Influenza Vaccine (LAIV)

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD), 2019-2032

Figure 5. Global Live Attenuated Influenza Vaccine (LAIV) Market Size (M USD) (2019-2032)

Figure 6. Global Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) & (2019-2032)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Live Attenuated Influenza Vaccine (LAIV) Market Size by Country (M USD)

Figure 11. Live Attenuated Influenza Vaccine (LAIV) Sales Share by Manufacturers in 2023

Figure 12. Global Live Attenuated Influenza Vaccine (LAIV) Revenue Share by Manufacturers in 2023

Figure 13. Live Attenuated Influenza Vaccine (LAIV) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Live Attenuated Influenza Vaccine (LAIV) Average Price (USD/MT) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Live Attenuated Influenza Vaccine (LAIV) Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Type

Figure 18. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2019-2024)

Figure 19. Sales Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2023

Figure 20. Market Size Share of Live Attenuated Influenza Vaccine (LAIV) by Type (2019-2024)

Figure 21. Market Size Market Share of Live Attenuated Influenza Vaccine (LAIV) by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application

Figure 24. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by

Application (2019-2024)

Figure 25. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Application in 2023

Figure 26. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application (2019-2024)

Figure 27. Global Live Attenuated Influenza Vaccine (LAIV) Market Share by Application in 2023

Figure 28. Global Live Attenuated Influenza Vaccine (LAIV) Sales Growth Rate by Application (2019-2024)

Figure 29. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region (2019-2024)

Figure 30. North America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 31. North America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2023

Figure 32. U.S. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 33. Canada Live Attenuated Influenza Vaccine (LAIV) Sales (K MT) and Growth Rate (2019-2024)

Figure 34. Mexico Live Attenuated Influenza Vaccine (LAIV) Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 36. Europe Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2023

Figure 37. Germany Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 38. France Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 39. U.K. Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 40. Italy Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 41. Russia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 42. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)

Figure 43. Asia Pacific Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2023

Figure 44. China Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 45. Japan Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 46. South Korea Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 47. India Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 48. Southeast Asia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 49. South America Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)

Figure 50. South America Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Country in 2023

Figure 51. Brazil Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 52. Argentina Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 53. Columbia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 54. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (K MT)

Figure 55. Middle East and Africa Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 57. UAE Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 58. Egypt Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 59. Nigeria Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 60. South Africa Live Attenuated Influenza Vaccine (LAIV) Sales and Growth Rate (2019-2024) & (K MT)

Figure 61. Global Live Attenuated Influenza Vaccine (LAIV) Production Market Share by Region (2019-2024)

Figure 62. North America Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2019-2024)

Figure 63. Europe Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth

Rate (2019-2024)

Figure 64. Japan Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2019-2024)

Figure 65. China Live Attenuated Influenza Vaccine (LAIV) Production (K MT) Growth Rate (2019-2024)

Figure 66. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Volume (2019-2032) & (K MT)

Figure 67. Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Value (2019-2032) & (M USD)

Figure 68. Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share Forecast by Type (2025-2032)

Figure 69. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Type (2025-2032)

Figure 70. Global Live Attenuated Influenza Vaccine (LAIV) Sales Forecast by Application (2025-2032)

Figure 71. Global Live Attenuated Influenza Vaccine (LAIV) Market Share Forecast by Application (2025-2032)

I would like to order

Product name: Global Live Attenuated Influenza Vaccine (LAIV) Market Research Report 2024, Forecast to 2032

Product link: <https://marketpublishers.com/r/GFCD080E407CEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFCD080E407CEN.html>